Effect of Omega-3 fatty acids on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patients
Volume 4, Issue 3, Summer 2015, Pages 135-141
. Afsoon Emami Naini, . Nooshin Keyvandarian, . Mojgan Mortazavi, . Shahram Taheri, . Sayed Mohsen Hosseini
Abstract Objective: Hypertension and hyperlipidemia are two major risk factors for cardiovascular disease
in continuous ambulatory peritoneal dialysis (CAPD) patients. This study was designed to investigate
the effect of omega-3 fatty acids on blood pressure (BP) and serum lipids in CAPD patients.
Methods: This study was a randomized double‑blind clinical trial in which 90 CAPD patients
were randomly assigned to either the omega‑3 or the placebo group. Patients in omega‑3
group received 3 g/day omega‑3 for 8 weeks, whereas patients in the control group received
placebo. At baseline and at the end of 8 weeks, the patients’ BP was controlled, and serum
biochemistry was measured.
Findings: Mean systolic BP decreased (–22.2 ± 14.2 mmHg) in the omega‑3 group at the end
of the study while in the placebo group increased (+0.5 ± 30.2 mmHg) (P < 0.0001). Mean
diastolic BP of the omega‑3 group decreased more (–11.95 ± 11.9 mmHg) comparing with
the placebo group (–1.1 ± 17.3 mmHg) (P = 0.001). There were no significant differences
between the two groups in mean changes in serum triglyceride, and total, high‑density
lipoprotein, and low‑density lipoprotein cholesterol.
Conclusion: The results of this study indicate that omega‑3 reduced BP significantly but
had no effect on lipid profile in our CAPD patients.